117 related articles for article (PubMed ID: 21414781)
1. Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.
Aso K; Kobayashi K; Mochizuki M; Kanzaki N; Sako Y; Yano T
Bioorg Med Chem Lett; 2011 Apr; 21(8):2365-71. PubMed ID: 21414781
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
[TBL] [Abstract][Full Text] [Related]
3. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
4. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Nielsen DM; Carey GJ; Gold LH
Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
[TBL] [Abstract][Full Text] [Related]
6. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
Müller CE; Geis U; Grahner B; Lanzner W; Eger K
J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
[TBL] [Abstract][Full Text] [Related]
7. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
[TBL] [Abstract][Full Text] [Related]
8. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
[TBL] [Abstract][Full Text] [Related]
9. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
[TBL] [Abstract][Full Text] [Related]
10. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
[TBL] [Abstract][Full Text] [Related]
11. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Kohno H; Sugimoto I; Matsushita T; Nishiyama T; Hirota T; Takeda H; Matsumura N; Ueno S; Kishi A; Kagamiishi Y; Nakai H; Takaoka Y
Bioorg Med Chem; 2012 Jan; 20(2):1122-38. PubMed ID: 22196514
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
[TBL] [Abstract][Full Text] [Related]
13. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
Gannon RL; Millan MJ
Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
[TBL] [Abstract][Full Text] [Related]
14. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
[TBL] [Abstract][Full Text] [Related]
15. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
16. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
Di Fabio R; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Sabbatini FM; Andreotti D; Spada S; Marchioro C; Worby A; St-Denis Y
J Med Chem; 2008 Nov; 51(22):7273-86. PubMed ID: 18975927
[TBL] [Abstract][Full Text] [Related]
18. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
Gordon JC; Edwards P; Elmore CS; Lazor LA; Paschetto K; Bostwick R; Sylvester M; Mauger R; Scott C; Aharony D
Eur J Pharmacol; 2010 Dec; 649(1-3):59-63. PubMed ID: 20854803
[TBL] [Abstract][Full Text] [Related]
19. Heteroaryl-substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine derivatives as potent and selective corticotropin-releasing factor receptor-1 antagonists.
Sabbatini FM; Di Fabio R; St-Denis Y; Capelli AM; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Micheli F; Pavone F; Rinaldi M; Pasquarello A; Zampori MG; Di Felice P; Zarantonello P; Arban R; Perini B; Vitulli G; Benedetti R; Oliosi B; Worby A
ChemMedChem; 2008 Feb; 3(2):226-9. PubMed ID: 18000940
[No Abstract] [Full Text] [Related]
20. [(76) Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor.
Jagoda EM; Lang L; McCullough K; Contoreggi C; Kim BM; Ma Y; Rice KC; Szajek LP; Eckelman WC; Kiesewetter DO
Synapse; 2011 Sep; 65(9):910-8. PubMed ID: 21308801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
